Advancing Brain Targeting: Cost-Effective Surface-Modified Nanoparticles for Faster Market Entry
Pharmaceutics · 17.05.2025 · 17 (5) · 661
DOI: 10.3390/pharmaceutics17050661 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 17.05.2025. Verfasst von Mariana Gomes und 3 weiteren Autor:innen. Beteiligte Einrichtung: LEPABE-Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias,…. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 154 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação para a Ciência e Tecnologia, FCT/MCTES (PIDDAC), ALiCE.
Abstract (Originalsprache)
Background/Objectives: The blood–brain barrier (BBB) poses a major obstacle to delivering therapeutic agents to the central nervous system (CNS), driving the need for innovative drug delivery strategies. Among these, nanoparticles (NPs) have gained attention due to their ability to enhance drug transport, improve bioavailability, and enable targeted delivery.
Methods
This paper explores various surface modification strategies employed to optimize NP-mediated drug delivery across the BBB. Specifically, the functionalization of NPs with ligands such as transferrin (Tf), lactoferrin (Lf), protamine, and insulin is discussed, each demonstrating unique mechanisms for enhancing brain-targeting efficiency. In addition, this work provides a comprehensive overview of recent scientific advancements and market strategies aimed at accelerating the adoption of low-cost, surface-modified nanoparticles, ultimately improving patient access to effective CNS treatments.
Conclusions
Preclinical and in vitro studies have demonstrated the effectiveness of these modifications in increasing drug retention and bioavailability in brain tissues. Additionally, while ligand-conjugated NPs hold significant promise for neuropharmacology, their clinical translation is often hindered by regulatory and economic constraints. Lengthy approval processes can slow market entry, but cost–benefit analyses indicate that surface-modified NPs remain financially viable, particularly as scalable manufacturing techniques and some ligands are cost-efficient.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- LEPABE-Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal.
- ALiCE-Associate Laboratory in Chemical Engineering, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal.
- Department of Mechanical Engineering, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal.
ORCID-Profile: Maria João Ramalho, Joana A Loureiro, Maria Carmo Pereira
Förderung
- Fundação para a Ciência e Tecnologia
- FCT/MCTES (PIDDAC)
- ALiCE
- Scientific Employment Stimulus - Individual Call
- M-ERA-NET3 network “ERA-NET for research and innovation in materials and battery technologies”
- Foundation for Science and Technology
- Project Nano4Glio that was selected in the Joint Transnational Cofund Call 2021 of M-ERA.NET 3
Zitieren
APA
Gomes, M., Ramalho, M. J., Loureiro, J. A., & Pereira, M. C. (2025). Advancing Brain Targeting: Cost-Effective Surface-Modified Nanoparticles for Faster Market Entry. Pharmaceutics, 17(5), 661. https://doi.org/10.3390/pharmaceutics17050661
Vancouver
Gomes M, Ramalho MJ, Loureiro JA, Pereira MC. Advancing Brain Targeting: Cost-Effective Surface-Modified Nanoparticles for Faster Market Entry. Pharmaceutics. 2025;17(5):661. doi:10.3390/pharmaceutics17050661
BibTeX
@article{Gomes2025,
author = {Gomes, Mariana and Ramalho, Maria João and Loureiro, Joana A and Pereira, Maria Carmo},
title = {Advancing Brain Targeting: Cost-Effective Surface-Modified Nanoparticles for Faster Market Entry},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {5},
pages = {661},
doi = {10.3390/pharmaceutics17050661}
}
EUVIMED